CLSD - Clearside Biomedical, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Clearside Biomedical, Inc.

900 North Point Parkway
Suite 200
Alpharetta, GA 30005
United States
(678) 270-3631

Full Time Employees36

Key Executives

NameTitlePayExercisedYear Born
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.Pres, CEO & Director816.4kN/A1952
Mr. Charles A. DeignanChief Financial Officer536.95kN/A1964
Dr. Thomas A. Ciulla M.B.A., M.D.Chief Medical Advisor-Retina597.21kN/A1965
Ms. Jenny R. KobinHead of Investor RelationsN/AN/A1967
Mr. Rick McElhenyVP of Corp. Devel.N/AN/AN/A
Mr. Rafael V. AndinoSr. VP of Engineering & ManufacturingN/AN/A1965
Ms. Susan L. Coultas Ph.D.Chief Clinical OfficerN/AN/AN/A
Mr. Leslie B. ZacksSec.N/AN/A1969
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Clearside Biomedical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.